CHICAGO, Sept. 3, 2019 /PRNewswire/ -- At the American Society for Radiation Oncology (ASTRO) 2019 Annual Meeting, September 15-18 in Chicago, Elekta (EKTA-B.ST) will highlight its growing portfolio of innovative solutions that are making Precision Radiation Medicine the new standard in value-based healthcare

BASEL, Switzerland, Sept. 3, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclud

STOCKHLOM, Sept. 3, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it has obtained written feedback from the US Food and Drug Administration (FDA) that will have a significant impact on the ongoing pivotal Phase 3 study, NefIgArd, with Calliditas' leading drug candidate Nefecon for the chronic autoimmune kidney disease IgA Nephropathy (IgAN). Cal

GDAŃSK, Poland, Sept. 3, 2019 /PRNewswire/ -- Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Under this agreement, Polph

SHANGHAI, Sept. 3, 2019 The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma Group recently took place in Nanjing. Dozens of psychiatrists and experts from 8 countries and regions including China, Korea, Malaysia, and Thaila

BERKELEY, Calif., Sept. 3, 2019 /PRNewswire/ -- The U.S. Patent and Trademark Office (USPTO) today awarded a new CRISPR-Cas9 patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering compositions of single molecule DNA-targetin

BALTIMORE, Sept. 2, 2019 /PRNewswire/ -- After Julie Odar's water broke at 16 weeks (Preterm Premature Rupture ofMembranes or PPROM), doctors advised that nothing could be done to safely continue the pregnancy. Against all odds, Julie managed to stay pregnant for 17 days before learning that her child had passed away; Julie delivered baby

FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time

MILAN and BASEL, Switzerland, Sept. 2, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over 50 world-leading experts fro

PITTSBURGH, Sept. 2, 2019 /PRNewswire/ -- "I was working in my shop, and I grew tired of having to go into the house every time I needed to wash my hands," said an inventor from Missouri City, Texas. "This inspired me to develop a convenient mobile hand-washing station that can be set up and used wherever it is needed."